Doutreleau Stéphane, Mettauer Bertrand, Piquard François, Schaefer Adrien, Lonsdorfer Evelyne, Richard Ruddy, Geny Bernard
Service de Physiologie Clinique et d'Exploration Fonctionnelle, Hôpitaux Universitaires de Strasbourg, France.
Can J Appl Physiol. 2005 Aug;30(4):419-32. doi: 10.1139/h05-131.
The purpose of this study was to determine, in heart failure patients (HF), whether acute or chronic L-arginine supplementation (LAS) might delay the ventilatory threshold (VT) and whether chronic LAS might reduce exercise-induced plasma lactate increase. HF patients undertook 4 cardiopulmonary bicycle exercises tests. The first 3 were maximal without (EX(1)), after acute (EX(2)), or chronic (EX(3)) oral LAS (6 gm twice a day for 6 weeks). The 4th test (EX(4)) performed after chronic LAS, was similar to the first in order to investigate the effect of chronic LAS on circulating lactate levels. Results showed that acute LAS failed to improve both submaximal and maximal exercise capacities. Similarly, maximal exercise capacity remained unmodified after chronic LAS. Nevertheless, chronic LAS delayed significantly the patients' ventilatory threshold. Thus exercise duration prior to VT increased (mean +/- SEM) from 6.04 +/- 0.9 to 7.7 +/- 1.03 min (p = 0.04), resulting in a significant increase in oxygen uptake (1.05 +/- 0.08 to 1.24 +/- 0.12 L.min(-1); p = 0.03), CO(2) release (0.94 +/- 0.10 to 1.2 +/- 0.12 L.min(-1); p = 0.018), minute ventilation (29.31 +/- 2.8 to 34.5 +/- 2.7 L; p = 0.009), and workload (60.7 +/- 9.8 to 78.5 +/- 10.2 watts; p = 0.034). Furthermore, chronic LAS significantly reduced the exercise-induced increase in postexercise plasma lactate concentration (-21 +/- 7%). In conclusion, unlike acute supplementation, chronic LAS significantly delays the ventilatory threshold, and chronic LAS reduces circulating plasma lactate in HF patients. These data suggest that chronic LAS might improve the ability of HF patients to perform their daily-life activities.
本研究的目的是确定,在心力衰竭患者(HF)中,急性或慢性补充L-精氨酸(LAS)是否可能延迟通气阈值(VT),以及慢性LAS是否可能减少运动诱导的血浆乳酸增加。HF患者进行了4次心肺自行车运动测试。前3次是在未补充(EX(1))、急性补充(EX(2))或慢性补充(EX(3))口服LAS(每天两次,每次6克,持续6周)的情况下进行的最大运动测试。第4次测试(EX(4))在慢性LAS后进行,与第一次相似,以研究慢性LAS对循环乳酸水平的影响。结果表明,急性LAS未能改善次最大和最大运动能力。同样,慢性LAS后最大运动能力保持不变。然而,慢性LAS显著延迟了患者的通气阈值。因此,VT之前的运动持续时间(平均值±标准误)从6.04±0.9增加到7.7±1.03分钟(p = 0.04),导致摄氧量显著增加(从1.05±0.08增加到1.24±0.12升·分钟-1;p = 0.03),二氧化碳释放量(从0.94±0.10增加到1.2±0.12升·分钟-1;p = 0.018),分钟通气量(从29.31±2.8增加到34.5±2.7升;p = 0.009)和工作量(从60.7±9.8增加到78.5±10.2瓦;p = 0.034)。此外,慢性LAS显著降低了运动诱导的运动后血浆乳酸浓度增加(-21±7%)。总之,与急性补充不同,慢性LAS显著延迟通气阈值,并且慢性LAS降低HF患者循环血浆乳酸水平。这些数据表明,慢性LAS可能改善HF患者进行日常生活活动的能力。